GMAB regulatory event: an FDA approval, -1.1%

On September 22, 2023, Epcoritamab — Genmab A/S (Diffuse Large B-Cell Lymphoma) reached its regulatory event. The result was an FDA approval, and the stock moved -1.1% in the window around the event.